Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Nov 4, 2015; 4(4): 274-277
Published online Nov 4, 2015. doi: 10.5492/wjccm.v4.i4.274
Published online Nov 4, 2015. doi: 10.5492/wjccm.v4.i4.274
Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?
Athanasios Papathanasiou, George Nakos, Intensive Care Unit, University Hospital of Ioannina, 45500 Ioannina, Greece
Author contributions: Both authors contributed equally to this editorial.
Conflict-of-interest statement: George Nakos declares no conflict of interest related to this publication. Athanasios Papathanasiou declares no conflict of interest related to this publication.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: George Nakos, MD, PhD, DTM, FCCP, Professor, Intensive Care Unit, University Hospital of Ioannina, PO Box 1186, 45500 Ioannina, Greece. gnakos@cc.uoi.gr
Telephone: +30-26-51099279 Fax: +30-26-51099353
Received: May 25, 2015
Peer-review started: May 26, 2015
First decision: July 10, 2015
Revised: August 11, 2015
Accepted: September 10, 2015
Article in press: September 16, 2015
Published online: November 4, 2015
Peer-review started: May 26, 2015
First decision: July 10, 2015
Revised: August 11, 2015
Accepted: September 10, 2015
Article in press: September 16, 2015
Published online: November 4, 2015
Core Tip
Core tip: Pulmonary arterial hypertension (PAH) is a rare disease that concerns a small population of patients. Recently, there has been a significant number of research, publications and novel therapies concerning PAH. However, pulmonary hypertension (PH), that concerns a much larger population of patients with common diseases such as lung and left heart diseases (LHD), is generally overlooked despite the fact that it significantly affects the prognosis of these patients. This editorial underlines the need for further research in regard to the pathogenesis and novel therapies for PH related to lung and LHD.